VEGFA and gastric cancer: It was demonstrated that anti-VEGF tyrosine kinase inhibitors (sunitinib, sorafenib, apatinib, trebananib, and regorafenib) combined with chemotherapy significantly improve the overall survival rates as well as the progression-free survival of patients with advanced GC [124–126].